Published in Cancer Res on September 15, 1997
The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci U S A (2005) 1.80
The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol (2005) 1.19
Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate (2008) 1.06
PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle. Am J Pathol (2003) 0.99
Identification of the GATA factor TRPS1 as a repressor of the osteocalcin promoter. J Biol Chem (2009) 0.94
Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer. Br J Cancer (1999) 0.90
Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br J Cancer (2000) 0.87
Increased expression of TRPS1 affects tumor progression and correlates with patients' prognosis of colon cancer. Biomed Res Int (2013) 0.85
BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy. Oncotarget (2015) 0.84
The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. Prostate (2013) 0.84
In silico analysis identifies a novel role for androgens in the regulation of human endometrial apoptosis. J Clin Endocrinol Metab (2011) 0.83
Systematic investigation of lycopene effects in LNCaP cells by use of novel large-scale proteomic analysis software. Proteomics Clin Appl (2007) 0.83
Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations. Am J Pathol (1999) 0.81
The Role of Tricho-Rhino-Phalangeal Syndrome (TRPS) 1 in Apoptosis during Embryonic Development and Tumor Progression. Cells (2013) 0.79
Basic science of hormonal therapy for prostate cancer. Rev Urol (2001) 0.77
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab (1998) 2.45
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol (1992) 2.21
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res (1998) 2.10
In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin. Prostate (1995) 2.07
Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem (1996) 2.05
Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem (1995) 2.02
Targeted disruption of the Insl3 gene causes bilateral cryptorchidism. Mol Endocrinol (1999) 1.99
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J Natl Cancer Inst (2000) 1.78
The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol (1991) 1.72
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68
Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet (1997) 1.66
Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun (1988) 1.64
Adrenal glands of mouse and rat do not synthesize androgens. Life Sci (1992) 1.64
Nuclear import of the human androgen receptor. Biochem J (1993) 1.58
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer (2013) 1.55
Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry (1992) 1.44
The N-terminal domain of the human androgen receptor is encoded by one, large exon. Mol Cell Endocrinol (1989) 1.38
Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res (1992) 1.34
Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol (1996) 1.29
Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol (1998) 1.26
Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Acta (1991) 1.24
Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry (1997) 1.24
Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol (1992) 1.18
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer (1999) 1.16
17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. J Clin Endocrinol Metab (1999) 1.16
Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis (1997) 1.13
Aberrant splicing of androgen receptor mRNA results in synthesis of a nonfunctional receptor protein in a patient with androgen insensitivity. Proc Natl Acad Sci U S A (1990) 1.10
High-affinity binding of oestradiol-17beta by cytosols from testis interstitial tissue, pituitary, adrenal, liver and accessory sex glands of the male rat. Biochem J (1974) 1.09
Involvement of insulin-like factor 3 (Insl3) in diethylstilbestrol-induced cryptorchidism. Endocrinology (2000) 1.09
Steroid hormone receptor phosphorylation: is there a physiological role? Mol Cell Endocrinol (1994) 1.08
Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs (2001) 1.08
Domains of the human androgen receptor and glucocorticoid receptor involved in binding to the nuclear matrix. J Cell Biochem (1995) 1.07
The androgen receptor in prostate cancer. Pathol Res Pract (1996) 1.06
An exonic point mutation of the androgen receptor gene in a family with complete androgen insensitivity. Am J Hum Genet (1990) 1.06
Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer (2004) 1.06
Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate (1993) 1.05
Characterization of the human androgen receptor transcription unit. J Biol Chem (1991) 1.03
Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J Biol Chem (1993) 1.03
Detailed functional studies on androgen receptor mild mutations demonstrate their association with male infertility. Clin Endocrinol (Oxf) (2007) 1.02
Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods (2009) 1.00
EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene (2000) 0.99
Differential hormone-dependent transcriptional activation and -repression by naturally occurring human glucocorticoid receptor variants. Mol Endocrinol (1997) 0.98
Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice. J Steroid Biochem Mol Biol (1990) 0.98
Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer (2001) 0.98
Hormone-dependent androgen receptor phosphorylation is accompanied by receptor transformation in human lymph node carcinoma of the prostate cells. J Biol Chem (1991) 0.98
Functional domains of the human androgen receptor. J Steroid Biochem Mol Biol (1992) 0.97
Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology (1997) 0.97
Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry (1994) 0.97
Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate (1993) 0.97
Structure and function of GC79/TRPS1, a novel androgen-repressible apoptosis gene. Apoptosis (2002) 0.96
Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J Steroid Biochem Mol Biol (1991) 0.96
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Br J Cancer (2009) 0.95
Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation. Hum Gene Ther (2011) 0.95
Phosphotryptic peptide analysis of the human androgen receptor: detection of a hormone-induced phosphopeptide. Biochemistry (1995) 0.95
The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res (1997) 0.94
Androgen receptor phosphorylation. Endocr Res (1996) 0.94
Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res (2000) 0.94
Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol (1990) 0.93
Structural organization of the human androgen receptor gene. J Mol Endocrinol (1989) 0.93
Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: an unusual type of intronic mutation. Am J Hum Genet (1997) 0.93
Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet (1993) 0.93
Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processed, paraffin-embedded human tissues after microwave pre-treatment. J Histochem Cytochem (1994) 0.93
The mouse androgen receptor. Functional analysis of the protein and characterization of the gene. Biochem J (1991) 0.93
Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol (1996) 0.92
Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol (2003) 0.92
Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology (1995) 0.92
Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab (1995) 0.92
Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells. Cancer Res (2001) 0.91
Neutrons and X-rays, comparative studies with Drosophila melanogaster. 1. The viability and fertility of induced autosomal translocations. Mutat Res (1981) 0.91
Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry (1998) 0.91
Hormonal control of gubernaculum development during testis descent: gubernaculum outgrowth in vitro requires both insulin-like factor and androgen. Endocrinology (2000) 0.91
Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study. Endocr Relat Cancer (2005) 0.91
Differential splicing of human androgen receptor pre-mRNA in X-linked Reifenstein syndrome, because of a deletion involving a putative branch site. Am J Hum Genet (1994) 0.91
Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol (1981) 0.90
Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer. Br J Cancer (1999) 0.90
Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol (1997) 0.89
The use of steroid-containing Silastic implants in male nude mice: plasma hormone levels and the effect of implantation on the weights of the ventral prostate and seminal vesicles. Prostate (1984) 0.88
An oestradiol receptor in rat testis interstitial tissue. FEBS Lett (1972) 0.88
Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells. Int J Cancer (1997) 0.88
Synthesis and post-translational modification of the androgen receptor in LNCaP cells. Mol Cell Endocrinol (1991) 0.88
Mosaicism due to a somatic mutation of the androgen receptor gene determines phenotype in androgen insensitivity syndrome. J Clin Endocrinol Metab (1997) 0.87
Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring. J Natl Cancer Inst (1987) 0.87
Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. J Steroid Biochem Mol Biol (1993) 0.87
Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer. J Pathol (2007) 0.87
Etiological studies of severe or familial hypospadias. J Urol (2001) 0.87
Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res (1995) 0.87
Androgen receptor heterogeneity in LNCaP cells is caused by a hormone independent phosphorylation step. J Steroid Biochem Mol Biol (1992) 0.87
Localization and hormonal stimulation of phosphorylation sites in the LNCaP-cell androgen receptor. Biochem J (1993) 0.87
Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br J Cancer (2000) 0.87
Modulation of glucocorticoid receptor expression in human bronchial epithelial cell lines by IL-1 beta, TNF-alpha and LPS. Eur Respir J (1996) 0.87